Publications by authors named "J E Hamer-Maansson"
Article Synopsis
- Hydroxyurea is typically the first choice for treating high-risk essential thrombocythemia (ET), but some patients can't tolerate it or don't respond, leading to the use of ruxolitinib as an alternative.
- A post hoc analysis compared clinical outcomes between patients who continued with hydroxyurea and those who switched to ruxolitinib after experiencing issues with hydroxyurea.
- Results showed that after switching to ruxolitinib, patients experienced significant reductions in both leukocyte and platelet counts over 48 months, demonstrating that ruxolitinib can be an effective option for patients with ET who are intolerant or refractory to hydroxyurea.
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by clonal proliferation of hematopoietic progenitor cells and is associated with an increased risk of thrombotic events (TEs). Established risk factors for TEs in patients with PV include advanced age, TE history, and elevated hematocrit. Although an association of TE with elevated white blood cell (WBC) counts has been suggested by retrospective studies, this relationship needs further validation.
View Article and Find Full Text PDFBackground: In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).
Methods: This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.
Results: The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.
The pharmacokinetics (PK) of dapagliflozin and metformin administered as fixed-dose combination (FDC) tablets (2.5 mg dapagliflozin/850 mg metformin or 5 mg dapagliflozin/1000 mg metformin) or as separate tablets in healthy subjects were evaluated in 2 separate studies. Study 1 evaluated PK by measuring mean ratios of area under the plasma concentration-time curve (time zero to infinity [AUCinf ]), AUC from zero to time of last measurable concentration (AUC0-t ), and maximum observed plasma concentration (Cmax ) for single-component or FDC tablets following a non-high-fat meal.
View Article and Find Full Text PDF